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                                     INTRODUCTION
Group  A  Streptococcal  infections  and  their  late  sequelae  like 
rheumatic  fever  and rheumatic  heart  disease  remain  an  important  and 
major health problem in India. The incidence of rheumatic fever varies 
from 0.2 to 0.75 per 1000 children per year in school children of age 5 to 
15 years. The prevalence of rheumatic heart disease varies from 1 to 5.4 
per  1000    children  1.  Such  data  have  emphasized  the  importance  of 
accurate  clinical  diagnosis  often  requiring  laboratory  confirmation  of 
preceding Group A streptococcal infection. 
Group A streptococcus also known, as Streptococcus pyogenes is a 
common cause of infections of upper respiratory tact and the skin in the 
children.  It  is  less  common  cause  of  perianal  cellulitis,  vaginitis, 
septicemia,  pneumonia,  endocarditis,  pericarditis,  osteomyelitis, 
suppurative  arthritis,  myositis,  cellulitis,  and  omphalitis.   These 
microorganisms  are  also  the  cause  of  two  distinct  clinical  conditions 
scarlet  fever  and  erysipelas,  as  well  as  toxic  shock  syndrome  and 
necrotizing  fascitis.  Group  A  Streptococcus  is  also  the  cause  of  two 
potentially  serious  non-suppurative  complications  namely  rheumatic 
fever and acute glomerulo nephritis. 
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STEPTOCOCCUS:
Streptococci  are gram-positive cocci  arranged in chains or pairs. 
They  are  part  of  normal  flora  of  humans  and  animals.  Some  are 
pathogenic. Most important of them is Streptococcus pyogenes.
CLASSIFICATION:
Several  systems  of  classification  have  been  employed  but  in 
medical bacteriology the following method is useful.
Streptococci  are  first  divided  into  obligate  anaerobes  and 
facultative anaerobes. The obligate anaerobe is peptostreptococcus. The 
aerobic and facultative anaerobe is classified on the basis of hemolysis on 
5% horse blood agar pour plate cultures as 
1. alpha hemolytic streptococci
2. beta hemolytic streptococci
3. gamma hemolytic streptococci
Alpha  hemolytic  streptococci  produce  a  greenish  discolouration 
with  partial  hemolysis  around the  colonies.  The  zone  of  hemolysis  is 
small, (1 – 2 mm wide) with indefinite margins and unlysed erythrocytes 
can be made out microscopically within this zone. The alpha streptococci 
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are  normal  commensals  in  the  throat,  but  may  cause  opportunistic 
infections rarely. Streptococcus viridans and pneumococci belong to this 
group.
A Beta hemolytic streptococci produce a sharply defined clear colourless 
zone  of  hemolysis,  2  –  4  mm  wide,  within  which  the  red  cells  are 
completely lysed. The term “hemolytic streptococci” strictly applies only 
to beta lytic strains. Most pathogenic streptococci are belonging to this 
group.
Gama  hemolytic  streptococci  are  non  hemolytic,  producing  no 
change in medium, so referred to as indifferent streptococci. They include 
fecal  streptococci  (enterococci,  streptococcus  faecalis)  and  related 
species. They are called the enterococcus group.
Beta hemolytic were classified by Lancefield (1933) into groups 
based on the carbohydrate antigen on the cell wall known as Lancefield 
groups,  twenty  of  which  have  been  identified.  The  great  majority  of 
hemolytic streptococci that produce human infections belong to group A. 
These are further subdivided into types based on protein antigens (M, T, 
and R) present on the cell surface (Griffith typing).  About eighty types of 
streptococcus pyogenes have been identified so far.
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STREPTOCOCCUS PYOGENES:
It  is  an  aerobe  and  a  facultative  anaerobe  growing  best  at  a 
temperature of 37°C.  It ferments several sugars, producing acid but no 
gas.  It  is  catalase  negative.  Hydrolysis  of  pyrrolidonyl 
naphthylamide(PYR)  ,  failure  to  ferment  ribose   and  sensitivity  to 
bacitracin  are  useful  in  differentiating  streptococcus  pyogenes  from 
others .
ANTIGENIC STRUCTURE:
 The  capsule  which  inhibits  phagocytosis  is  not  antigenic  in 
humans. The cell wall which is composed of an outer layer of protein and 
lipoteichoic acid ,  middle  layer  of  group specific  carbohydrate  and an 
inner layer of peptidoglycan . 
Several protein antigens have been identified in the outer part of 
cell  wall.  Streptococcus  pyogenes  can  be  typed  based  on  the  surface 
proteins M, T, R. The M protein is the most important of these. It acts as 
a  virulence  factor  by  inhibiting  phagocytosis.  Hair  like  pili  projects 
through the capsule of group A streptococcus. The pili consist partly of M 
protein and are covered with lipoteichoic acid which is important in the 
attachment of streptococcus to epithelial cells. 
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Various  structural  component  of  streptococcus  pyogenes  exhibit 
cross  reaction  with  different  tissues  of  the  human  body.  Antigenic 
relationships have been demonstrated between capsular hyaluronic acid 
and human synovial fluid, cell  wall protein and myocardium, group A 
carbohydrate  and  cardiac  valves,  cytoplasmic  membrane  antigens  and 
vascular  intima,  and  peptidoglycans  and  skin  antigens.  It  has  been 
postulated that these antigenic cross reactions may account for some of 
the manifestations of rheumatic fever and other streptococcal diseases, 
the tissue damage being of immunological nature. 
Streptococcal components Mammalian tissue constituent
Streptococcal hyaluronic acid. Mammalian  hyaluronic  acid  and 
protein polysaccharide.
Group A carbohydrate. Glycoproteins of heart valves.
Protein cell wall. Sarcolemma of  cardiac  and  skeletal 
muscle.
Protein of cell membrane. Sarcolemma of  cardiac  and  skeletal 
muscle.
Glycoprotein of cell membrane. Glycoprotein of glomerular basement 
membrane.
Antigen of cell membrane. Histocompatibility antigen.
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TOXINS AND VIRULENCE FACTORS:
Streptococcus  pyogenes  forms  several  exotoxins  and  enzymes 
which  constitute  to  its  virulence.  Besides  these,  M  protein  and  C 
polysaccharide are also important. 
Cellular components Extra cellular components
Hyaluronic acid capsule Streptolysin S,O
Group specific carbohydrate Hyaluronidase
M T R proteins Streptokinase
Mucopeptide NADase
Poly glycerophosphate DNase
ß glucoronidase Erythrogenic toxin
Lipoproteinase Proteinase
DNA RNase
RNA Amylase
HEMOLYSINS – 
Group A streptococcus produce two hemolysins streptolysin O and 
S. streptolysin O is so called because it is oxygen labile and heat labile. It 
is antigenic in human and inhibited by cholesterol and toxic to variety of 
cell types including leucocytes monocytes and cultured cells. Because of 
its  oxygen lability  streptolysin O is  primarily  responsible  for  the beta 
hemolysis seen around sub surface colonies of group A streptococci in 
pour  plates  or  in  the  stabbed  regions  of  inoculated  sheep  blood  agar 
plates.  Streptolysin O is also produced by some group C and group G 
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streptococci. Antistreptolysin O appears in sera following streptococcal 
infection. Estimation of ASO is a standard serological procedure for the 
retrospective diagnosis of infection with streptococcus pyogenes. 
Streptolysin S is an oxygen stable hemolysin. It is not antigenic in 
humans and also toxic to variety of cell types. Streptolysin S is active in 
both surface and subsurface hemolysis when the organisms are grown on 
sheep blood agar.  Both streptolysin O and S can induce injury to non 
erythrocytic cell types causing the formation of slits and pores in the cell 
membrane and subsequent leakage of cellular contents.
PYROGENIC EXOTOXINS – (ERYTHROGENIC TOXINS):
It is also called as Dick, scarlatinal toxin. Three types of pyrogenic 
exotoxins are present. Type A, B and C. Type A has been most widely 
studied.  It  is  produced by group A streptococci  that  carry a  lysogenic 
phage and is a super antigen. The streptococcal pyrogenic exotoxins have 
been  associated  with  streptococcal  toxic  shock  syndrome  and  scarlet 
fever.  Streptococcal  pyrogenic exotoxins C may also contribute  to the 
syndrome,  while  the  role  of  exotoxin  B  is  unclear.  The  group  A 
streptococci  associated with toxic  shock syndrome are  primarily  of  M 
proteins type 1 and 3. 
STREPTOKINASE – (FIBRINOLYSIN) :
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This  promotes  lysis  of  human  fibrin  clots  by  activating 
plasminogen.  It  is  an  antigenic  protein.  Antistreptokinase  antibody 
provides retrospective evidence of streptococcal infection. Streptokinase 
appears to play a biological role in streptococcal infections by breaking 
down the fibrin barrier around the lesions and facilitating the spread of 
infections. Streptokinase is given intravenously for the treatment of early 
myocardial infarction and other thromboembolic disorders.
DEOXYRIBONUCLEASE - (STREPTODORNASE):
 This cause depolymerisation of DNA, which helps to liquefy the 
thick  pus  and  may  be  responsible  for  the  thin  serous  character  of 
streptococcal exudates. This property has been applied therapeutically in 
liquefying  localized  collections  of  thick  exudates  as  in  empyema.  A 
preparation containing streptokinase and streptodornase is available for 
this purpose.
 Four  antigenically  distinct  DNAase  A,  B,  C  and D have  been 
recognized of which type B is the most antigenic. Demonstration of anti-
DNAase  antibody  is  useful  in  the  retrospective  diagnosis  of 
Streptococcus  pyogenes  infection  particularly  in  skin  infection,  where 
ASO titers may be low.
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NICOTINAMIDE ADENINE DINUCLEOTIDASE (NADase) – 
It is formerly known as diphosphopyridine nucleotidase (DPNase). 
This  act  on  the  coenzyme  NAD and  liberates  nicotinamide  from the 
molecule.  It  is  antigenic  and  is  neutralized  by  the  antibody  in  the 
convalescent sera.
HYALURONIDASE – 
This  enzyme breaks  down the  hyaluronic  acid  of  the tissues.  It 
depolymerises  the  ground  substance  of  connective  tissue  resulting  in 
contiguous spread of organism.
 It is antigenic and specific antibodies appear in the convalescent 
sera. 
Many  strains  also  produce  serum  opacity  factor,  proteinase, 
phosphatase, esterase, amylase, N-acetyl glucosaminidase, neuraminidase 
and other toxins or enzymes.
STREPTOCOCCUS PHARYNGITIS:
Group A Streptococcus pharyngitis is one of the common bacterial 
infections in children. It accounts for 20 to 40 % of exudative pharyngitis 
in children. They are uncommon before 2 to 3 years of age. The incidence 
increases among children and then declines in late adolescence. It occurs 
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throughout the year but is reported most often during winter and spring. 
Illness often spread among siblings and classmates.
Colonization  of  pharynx  by  group  A  Streptococcus  may  result  in 
asymptomatic carriage or acute infection. The M protein is the major virulence factor. 
CLINICAL FEATURES: 
Onset of pharyngitis is often rapid with prominent sore throat and 
fever, headache and gastrointestinal symptoms are frequent. The pharynx 
is red and the tonsils are enlarged and classically covered with a yellow 
blood tinged exudate. The anterior cervical nodes are enlarged and tender.
DIAGNOSIS
THROAT SWAB CULTURE:
Throat  swab  culture  remains  the  gold  stranded  for  diagnosis  of 
streptococcus pharyngitis. False positivity can occur if other organisms 
are  misdiagnosed.  False  negative  cultures  are  attributed  to  inadequate 
specimen and patients on prior antibiotics. It has 90 to 95% sensitivity of 
detection. The disadvantage of throat swab is delay in culture result. 
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RAPID ANTIGEN DETECTION TESTS:
Rapid  antigen  detection  tests  have  been  developed  for 
identification of group A Streptococcus from throat swabs. These kits use 
enzymatic or chemical methods to extract the antigen from the swab, and 
then use enzyme immuno assay or agglutination tests to demonstrate the 
presence of the antigen. The tests can be completed minutes to hours after 
specimen is obtained.
 Although  they  are  expensive,  the  advantage  is  the  rapidity  of 
identification  and  treatment.  The  rapid  antigen  detection  tests  have 
excellent  specificity  of  more  than  95%  when  compared  to  culture. 
Unfortunately sensitivity of these tests is 80 to 90% possibly lower than 
culture. 
TREATMENT:
Most  untreated  episodes  of  streptococcal  pharyngitis  resolve 
uneventfully  in   few days but  early  antibiotic  therapy hastens  clinical 
recovery  by  12  -24  hours.  The  primary  benefit  of  treatment  is  the 
prevention  of  acute  rheumatic  fever,  which  is  almost  completely 
successful  if  antibiotic  treatment  is  instituted within 9 days of  illness. 
Antibiotic  therapy  should  be  started  immediately  without  culture  for 
children with symptomatic pharyngitis and a positive streptococcal rapid 
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antigen test;  clinical diagnosis of scarlet fever; household contact with 
documented streptococcal pharyngitis; a past history of acute rheumatic 
fever; or a recent history of acute rheumatic fever in a family member.
A  variety  of  antimicrobial  agents  are  effective.  Group  A 
streptococci  remains  universally  susceptible  to  penicillin,  which  has  a 
narrow spectrum and few adverse effects. Penicillin V  in a dose of 250 
mg BID or TID for 10 days for children and 250 to 500 mg per dose for 
adolescence and adults. Oral amoxicillin in a dose of 750 mg once daily 
for  10  days  is  also  effective.  Single  intramuscular  dose  of  benzathine 
penicillin (6, 00,000 IU for children less than 27 kg, 1.2 million units for 
larger  children  and  adults.)  or  benzathine  –  Procaine  penicillin  G 
combination  provides  adequate  blood  level  for  more  than  10  days. 
Erythromycin (erythromycin ethyl succinate 40 mg/kg/day divided TID 
or QID for 10 days or erythromycin esteolate 20 – 40 mg/kg/day divided 
BID, TID or QID for 10 days.) is recommended for patients allergic to 
beta  lactam  antibiotics.  The  treatment  regimen  most  effective  for 
eradicating  streptococcal  carriage  is  Clindamycin  20  mg/kg  per  day 
divided in 3 doses orally for 10 days.
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ACUTE RHEUMATIC FEVER:
First clinical description of rheumatic heart disease was reported by 
Rene T. Laennec in 1818, when he introduced the stethoscope. But the 
full syndrome of rheumatic fever was described by Cheadle in 1886. The 
correlation between the history of streptococcal sore throat and rheumatic 
fever was strongly suspected in early 1900s. 
Acute  rheumatic  fever  is  important  non suppurative sequelae  of 
groupA streptococcus infection of throat. Studies have shown that 2-3% 
of  individuals  with  untreated  group  A  Streptococcus  pharyngitis  will 
develop acute rheumatic fever .2  Acute rheumatic fever most often occurs 
in children with peak age related incidence between 5 to 15 years.
Epidemiological risk factors classically associated with individual 
attacks and especially with out breaks of acute rheumatic fever, include 
lower standard of living, over crowding, under nutrition and poverty. It is 
also more common in urban centers than in rural communities. It occurs 
in  all  races  and  in  all  parts  of  world.  Although  it  is  traditionally 
considered to be a disease of temperate climate, it is now more commonly 
reported in tropical climates, particularly in developing countries.
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The  disease  has  been  more  common  among  socially  and 
economically disadvantaged populations. However the outbreaks in US in 
late  1980s and early  1990s cannot  be explained by these factors.  The 
large Utagh outbreak of more than 600 cases during 17 years has affected 
mainly middle class people with ready to access medical care. Therefore 
one can conclude that the organism itself as well as the degree of host and 
herd   immunity to prevalent M types in an affected community is equally 
important risk factors.
THE GENETIC SUSCEPTIBILITY:
Relatively few individuals (2 – 3%) will develop rheumatic fever 
after acute streptococcal pharyngitis  2. However in those who have had 
previous  episodes  of  rheumatic  fever,  recurrence  will  occur  in 
approximately half 3. Children who develop rheumatic fever demonstrate 
an exaggerated antibody response to toxins produced by streptococcus 
(such  as  ASO)  compared  with  other  patients  who  recovered  from 
streptococcal pharyngitis and did not develop rheumatic fever 4.
Genetic  predisposition  is  evidenced  by  high  concordance  (20%) 
among monozygotic twins and by high incidence among Maoris of New 
Zealand compared with their Caucasians neighbours irrespective of their 
economic  and  social  status  5.  Further  evidence  is  provided  by  the 
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association of the disease with inheritance of HLA antigen markers (HLA 
– DR4, 2, 3, 1, 78; DR – 53, Dw 10) among different population and 
ethnic  groups  6,  by  the  productive  effect  of  HLA  DR  5  and  by  the 
association with high level of expression of B cell alloantigen D 8/17. 
The  genetic  susceptibility  to  rheumatic  fever  is  mediated  by  a  single 
recessive gene 7.
RHEUMATOGENIC STREPTOCOCCI:
Among  the  group  A  beta  hemolytic  streptococci,  there  are 
rheumatogenic strains causing rheumatic fever (1, 3, 5, 6, 18, 24) 8. Past 
and recent out breaks of both infections by group A streptococcus and 
rheumatic  fever  showed  highly  mucoid  colonies  in  samples  grown in 
blood agar 9. The mucoid appearance in the culture is probably a result of 
hydrolysis  of  the  capsule  hyaluronidase  that  is  produced  during  the 
growth of the organism.
PATHOGENISIS:
 Several  theories  of  pathogenesis  of  acute  rheumatic  fever  and 
rheumatic heart disease have been proposed, but only two are seriously 
considered.
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1) CYTOTOXIC THEORY: 
Group A streptococcus toxin may be involved in pathogenesis of 
acute  rheumatic  fever  and  rheumatic  heart  disease.  Group  A 
streptococcus produce several enzymes that are cytotoxic for mammalian 
cells.  For  example  antistreptolysin  O  has  a  direct  cytotoxic  effect  on 
mammalian  cells  in  tissue  culture  and  most  of  the  proponents  of  the 
cytotoxic theory have focused on this enzyme. However one of the major 
problems with the cytotoxicity hypothesis is its inability to explain the 
latent period between pharyngitis and onset of acute rheumatic fever.
2) IMMUNE MEDIATED THEORY: 
This has been suggested by clinical similarity of acute rheumatic 
fever to other illness produced by immunopathogenetic processes and by 
the  latent  period  between  group  A  Streptococcus  infection  and  acute 
rheumatic  fever.  The hypothesis  of  antigenic  mimicry between human 
and group A Streptococcus antigens has been studied extensively and 
concentrated  on  two  interactions.  First  is  similarity  between  group 
specific carbohydrate of group A Streptococcus and glycoprotein of heart 
valves,  and  second  involves  molecular  similarity  among  streptococcal 
cell membrane and M protein sarcolemma and other moieties of human 
myocardial cell.
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DIAGNOSIS:
Because  no  clinical  or  laboratory  finding  is  pathognomonic  for 
acute rheumatic fever T.Dukett Jones in 1944 proposed guidelines to aid 
in diagnosis and limit over diagnosis.  The most recent modification of 
Jones criteria (updated 1992) was published in 1992 by a special writing 
group of the American Heart Association 10.
JONES CRITERIA, UPDATED (1992).10
Major Minor
1) Carditis.
2) Poly arthritis.
3) Chorea.
4) Erythema marginatum.
5) Subcutaneous nodules.
Clinical findings:
   Fever
   Arthralgia.
Laboratory findings:
   Elevated acute phase reactants.
   ESR.
   CRP.
   Prolonged PR interval.
Supporting evidence for an antecedent group A streptococcal infection:
     Positive throat culture or rapid streptococcal antigen test. 
     Elevated or rising streptococcal antibody titer.
To fulfill the criteria either two major or one major and two minor 
plus evidence of an antecedent streptococcus infection are required. The 
latter may be provided by recovery of organism in culture or by evidence 
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of  immune  response  to  one  of  the  commonly  measured  group  A 
streptococcal antibodies like anti streptolysin O or anti DNAase B. 
Acute  rheumatic  fever  typically  develops  2 to  4  weeks  after  an 
acute  episode  of  group  A  streptococcus  pharyngitis,  at  a  time  when 
clinical findings of pharyngitis are no longer present and when only 10 to 
20 % of throat culture or rapid antigen test results are positive. In about 
one  third  of  patients  with  rheumatic  fever  will  not  have  a  history  of 
antecedent pharyngitis, moreover mere presence of organism can indicate 
carrier state which is seen in 2.5 to 35.4%. 11. Therefore evidence of an 
antecedent  group  A  streptococcus  is  usually  based  on  elevated  or 
increasing titers.
A slide agglutination test (streptozyme test)  has been introduced 
and it  is  purposed to  detect  antibodies  against  five  different  group A 
streptococcal antigens. Although this test is rapid and simple to perform 
and widely available, it  is less standardized and less reproducible than 
other tests and should not be used as a diagnostic test for evidence of 
group A Streptococcus infection. If only a single antibody is measured 
(usually ASO) only 80 to 85 % of patients with acute rheumatic fever 
have an elevated titer, however 95 to 100 % have an elevation of titer if 
three  different  antibodies  (ASO,  anti-DNase  B,  antihyaluranidase)  are 
measured. Therefore when acute rheumatic fever is suspected clinically, 
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multiple antibody tests are performed. 
Except  for  patients  with  chorea,  clinical  findings  of  acute 
rheumatic fever generally coincide with peak antistreptococcal antibody 
responses. The diagnosis of acute rheumatic fever should not be made in 
patients with elevated or increasing antibody titers, who do not fulfill the 
Jones  criteria,  because  such  titer  changes  maybe  coincidental.  This  is 
most often true in younger school aged children, may be of who have 
group  A  Streptococcus  pyoderma  in  summer  or  unrelated  group  A 
Streptococcus pharyngitis during winter and spring months.
Because  acute  rheumatic  fever  and  post  streptococcal 
glomerulonephritis  are  non-suppurative  sequelae  of  group  A 
Streptococcus  infection  and  there  is  a  latent  period  between  the 
streptococcal infection and onset of disease, serum taken at the disease 
onset may really be convalescent; a rising titer may not be demonstrated. 
Hence an upper limit of normal value (ULN) is useful when acute and 
convalescent sera unavailable12.  For the purpose of uniformity ULN is 
defined as that titer exceeded by 20% of normal population that is 80th 
percentile 13 .
Clinical  microbiological  laboratories  often  use  interpretative 
criteria  suggested  by  manufacturers  of  commercial  antibody  test  kits. 
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Because such ‘normal’ values may only reflect appropriate titer for adult, 
which is almost always lower than for children, can be problematic.  
TREATMENT:
All patients with rheumatic fever should be placed on bed rest and 
monitor closely for evidence of Carditis. 
ANTIBIOTIC THERAPY:
Once the diagnosis of the rheumatic fever has been established and 
regardless of throat culture results the patient should receive 10 days of 
oral  penicillin  or  erythromycin  or  a  single  intramuscular  injection  of 
Benzathine penicillin to eradicate group A streptococci from the upper 
respiratory tract, after this initial course of antibiotic therapy the patient 
should be started on long term antibiotic prophylaxis.
ANTI INFLAMMATORY THERAPY:
Patients with typical migratory polyarthritis and those with carditis 
without cardiomegaly or congestive cardiac failure should be treated with 
oral salicylates. The usual dose of aspirin is 100mg/kg/24 hours divided 
QID per oral for 3 to 5 days followed by 75mg/kg/24hours divided QID 
per oral for 4 weeks.
Patients with carditis and cardiomegaly or congestive heart failure 
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should receive corticosteroids. The usual dose of prednisolone is 2 mg/ 
kg / 24 hours in four divided doses for 2 – 3 weeks followed by a tapering 
of the dose that reduces the dose by 5 mg/ 24 hours every 2 – 3 days. At 
the beginning of tapering of prednisolone dose, aspirin should be started 
at 75 mg/ kg / 24 hours in four divided doses for 6 weeks. The supportive 
therapy  of  patients  with  moderate  to  severe  carditis  includes  digoxin, 
fluid  and salt  restriction,  diuretics  and oxygen.  The  cardio  toxicity  of 
digoxin is enhanced with myocarditis.
PREVENTION:
Prevention of both initial and recurrent episodes of acute rheumatic 
fever depends on controlling group A streptococcal infection of the upper 
respiratory tract. 
PRIMARY PREVENTION:
The prevention of initial attacks (primary prevention) depends on 
identification and eradication of group A streptococcus that produces the 
episodes  of  acute  pharyngitis.  Appropriate  antibiotic  therapy instituted 
before  the  nineth  day  of  symptoms  of  acute  group  A  streptococcal 
pharyngitis is highly effective in preventing first attack of rheumatic fever 
from that episode.
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SECONDARY PREVENTION:
Secondary  prevention  is  directed  at  preventing  acute  group  A 
streptococcal pharyngitis in patients at substantial risk of recurrent acute 
rheumatic fever. Individuals who have already suffered an attack of acute 
rheumatic fever  are  particularly  susceptible to recurrence of rheumatic 
fever with any group A streptococcal  upper respiratory tract  infection, 
whether  or  not  they  are  symptomatic.  Therefore  these  patients  should 
receive antibiotic prophylaxis to prevent recurrences.
Antibiotic Dose Mode
Benzathine penicillin 1,20,000  IU  every  3  -4 
weeks
Intra muscular
Penicillin V 250 mg BID Oral
Sulphadiazine 500 – 1000 mg OD Oral
Erythromycin  (allergy 
to penicillin)
250 mg BID Oral
Patients who did not have carditis with their initial episode of acute 
rheumatic fever have a relatively low risk of carditis with recurrences. 
Antibiotic prophylaxis may be discontinued in these patients when they 
reach their early twenties and after at least 5 years have elapsed since 
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their  last  episode  of  rheumatic  fever.  The  decision  to  discontinue 
prophylactic antibiotic should be made only after careful consideration of 
potential risks and benefits and of epidemiological factors such as the risk 
of exposure to group A streptococcal infections. 
Patients  who  have  carditis  with  their  initial  episode  of  acute 
rheumatic fever  are at  relatively increased risk of having carditis  with 
recurrences and of sustaining additional cardiac damage. So they should 
receive antibiotic prophylaxis well into adulthood and perhaps for life.
ANTISTREPTOLYSIN O:
Antistreptolysin  O  is  an  antibody  produced  by  human  against 
streptococcal  extra  cellular  enzyme  called  streptolysin  O.  It  starts 
appearing after 1 week of streptococcal infection especially pharyngitis. It 
rises rapidly and reaches maximum by about 3 to 4 weeks and then starts 
disappearing after  12 weeks.  This  is  not  specific for  any type of post 
streptococcal  disease,  but  indicates  if  a  streptococcal  infection  was 
present or not. Serial ASO titer testing is often performed to differentiate 
between acute and convalescent sera.
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False positives:
1) Fats  mainly  beta  lipoproteins  in  blood may  cause  false  high 
values of ASO by neutralizing streptolysin O.
2) Tuberculosis, liver disease mainly acute viral hepatitis and other 
bacterial contamination also can produce false high values.
3) Hemolysed blood samples also can produce false high values.
False negatives:
1) Antibiotic intake prior to sampling can reduce the number of 
streptococci, and there by reduce the ASO level.
2) Steroid  intake  also  reduces  ASO  by  causing  immune 
suppression.
3) Streptococcal skin infection may not cause significant raise in 
ASO titer. 
4)  20% of acute rheumatic fever itself can have normal ASO.
UNITS: 
ASO  can  be  measured  in  two  units;  they  are  Todd  units  and 
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International units per ml.
Todd unit; 
Defined  as  amount  of  serum  just  neutralizing  2  ½  minimum 
hemolytic  doses  of  a  standardized  streptolysin.  One  international  unit 
equals to 1.04 Todd units 14 .
METHODS TO DETERMINE ASO TITER:
1) HEMOLYTIC OR RANTZ RANDALL METHOD:
It is based on the properties of streptolysin O to produce hemolysis 
to a standardized rabbit  erythrocyte suspension.  Serial  dilutions of  the 
patient serum are mixed to 1 IU/ml of streptolysin O solution and the 
residual hemolytic activity is measured through the hemoglobin released 
by erythrocyte suspension on standard conditions. It is a semi quantitative 
method that has been used for several years as reference method. It is 
long and tedious.
2) LATEX METHOD:
It is based on the ability of ASO anti bodies present in the patient’s 
sera to agglutinate latex particles coated with streptolysin O molecules. It 
is a qualitative method important by its simplicity.
3) LIGHT SCATERING IMMUNO ASSAY
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These Immuno assays are based on the measurement of scattered 
or absorbed light, are an extension of the basic principles underlying that 
Latex agglutination tests. The change in the light scattered or blocked by 
Antibody  or  Antigen  in  solutions,  is  used  to  measure  the  amount  of 
antigen or antibody, when causes the immunological antigen - antibody 
precipitation or agglutination reactions. 
TURBIDIMETRY;
Turbidimetry  is  the  measurement  of  light  scattering  species  in 
solution by means of a decrease in intensity of the incident beam after it 
has passed through the solution.  For turbidimetry assays change in the 
amount of light absorbed  (inverse of amount transmitted) can be related 
to  the  amount  of  agglutination,  which  occurs.  Hence  the  amount  of 
analyte (the species causing agglutination in the sample) can be easily 
determined. 
Turbidity  is  measured at  180° from the incident  beam,  or  more 
simply  in  the  same  manner  as  absorption  measurement  are  made  in 
spectrophotometer.  The  turbidity  can  be  measured  on  most 
spectrophotometer and automated chemistry analyzers.
This has been designed to measure ASO concentration in the range 
of  50 – 800 IU/ml and it  is  linear  between the measuring ranges.  No 
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prozone effect was observed up to a concentration of 1250 IU/ml of ASO. 
No interference is observed with bilirubin up to 50 mg/dl glucose up to 
500mg/dl,  hemoglobin  up  to  500 mg/dl,  triglycerides  up  to  1g/dl  and 
albumin up to 10g/dl.
NEPHELOMETERY:
It  is  the  technique  for  measuring  the  light  scattering  species  in 
solution  by  means  of  the  light  intensity  at  an  angle  away  from  the 
incident light passing through the sample. Nephelometry assays present 
an indirect method of measurement of  the amount of analyte in a sample 
by measuring the amount of lights scattered or reflected  at a given angle 
(90°)  from the  origin.   Some  nephelometers  are  designed  to  measure 
scattered light at an angle other than 90° in order to take advantage of the 
increased forward scatter intensity caused by light scattering from larger 
particles (example immune complexes).
The choice between turbidimetry and nephelometry depends on the 
application and available instrumentation.  Until recently the statement 
was often made that for relatively clear solutions, in which transmission 
of light in the forward direction is greater than 95% small  changes in 
absorption due to turbidity were difficult to measure with precision, and 
nephelometry was the method of choice. However with advent of stable 
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high-resolution  photometric  systems,  turbidimetric  measurements  have 
become  competitive  in  sensitivity  with  nephelometric  methods  for 
immunological quantitations of serum protein.
ANTI-DNASE B:
This is an antibody against deoxyribonuclease B antigen produced 
by  group  A  Streptococcus.  It  is  also  used  to  diagnose  antecedent 
streptococcal  infection.  When  ASO  and  anti-DNase  B  are  done 
concurrently  95% of  previous  streptococcal  infections  are  detected.  If 
both are repeatedly negative the likelihood is that the symptoms are not 
due to Streptococcus.
When  the  diagnosis  of  acute  rheumatic  fever,  American  Heart 
Association recommends ASO rather  than anti-DNase B,  even though 
anti-DNase B is more sensitive than ASO, its results are too variable. It 
also should be noted that,  while  ASO is  the recommended test,  when 
ASO and anti-DNase B are done together, the combination is better than 
either of these alone.
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STREPTOZYME TEST:
It is a screening test to find out antibodies against five antigens like 
streptolysin O, DNase B, streptokinase,  NADase and hyaluronidase.  It 
has  advantages  over  ASO  and  anti-DNase  B.  it  can  detect  several 
antibodies in single assay. It is technically quick and easy to perform, and 
is  unaffected  by  factors  that  produce  false  positive  ASO.  It  has 
disadvantages’ also. As the test detects different antibodies, it does not 
determine which have has been detected, and it is not sensitive in children 
as compared to adults, the fact that borderline elevations, which could be 
significant  in  children,  may  not  be  detectable  at  all.  As  with  ASO a 
serially rising titer is more significant than single determination.       
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LITERATURE REVIEW
Sunil  sethi,  et  al  from Chandigarh have done ASO titer  on 200 
healthy children of 5 to 15 years. They have included children with no 
history of any recent throat infection in their study. ASO determination 
was done by stranded neutralization test.  Found to have geometric mean 
titer (GMT) of 111.63 IU and ULN of 238.59 IU for children of 5-15 
years. They also observed that GMT of  113.72 IU in 5 to 10 years and 
110.32 IU in 11 to 15 years age group. The ULN was found to be 230.62 
IU and  242.87  IU in  5  to  10  years  and  10  to  15  years  respectively. 
Though there was a difference in ULN in both age groups it  was not 
statistically significant 15.
M G Karmarkar,  et  al  from Mumbai  have  done ASO and anti-
DNase B for 40 children and 160 adults in 1991-92 and also in 2001-02 
of age and sex matched population. The inclusion criteria were volunteers 
with no features suggestive of sore throat in the past three months and no 
history of joint pain and not taken any antibiotic for the same. The ASO 
determination was done by tube dilution method. Found to have ULN of 
ASO 244 IU during 1991 and 305 IU during 2001in children. The adults’ 
value was 195 IU in both the years.  This study showed an upward shift 
of  ASO from 244 IU to  305 IU in  10  years  in  same population.  No 
significant seasonal variation was noted in both the years 16 .
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Danchin M H,  et  al  from Australia have done ASO titer  on 60 
children in 2002. The inclusion criteria: children with no history of recent 
streptococcal infection. This study showed higher values in age group of 
6-9 years. The ULN was 120 IU in 4-5 years, 480 IU in 6-9 years and 320 
IU in 10-14 years.17
Edward L Kaplan, et al from United States have estimated ASO 
titer on 1131 children of 2 to 12 years in 1994-99.  Inclusion criteria: 
children presented with pharyngitis and sera were taken on initial visit. 
Found to have GMT of 89 IU and ULN of 240 IU.  They concluded that 
this  age  specific  ASO are  increased  with  age  and  they  were  slightly 
higher than previously reported18
Zaman M M, et al from Bangladesh have estimated ASO titer on 
361 apparently healthy rural school children of 5 to 14 years, and found 
to  have  GMT  of  241  IU  and  ULN  of  390  IU.  The  ASO  titer  was 
measured by quantitative method using an auto analyzer.19
Berrios  X,  et  al  have  measured  ASO  on  135  healthy  children 
during 1986-89, and found to have GMT of 62 Todds unit in age group of 
5 to 9 years, 127 TU in 10 to 14 years and 114 TU in more than 15 years. 
There were no significant difference detected between these results and 
those from earlier 1978-81 studies.20
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Renneberg  J,  et  al  from Sweden  studied  upper  95% confidence 
limits for ASO titer on 741 sera from general population, shown that titer 
from children were increased abruptly with increasing age, from a mean 
of 21 units in children 3years of age or less to 211 units in 7 to 8 years. In 
children of 9 to 12 years exhibited a plateau with mean values of 168 to 
258 units.  In  age more than 20 years,  the mean titer  diminished with 
increasing age. Individuals with age more than 70 years showed a mean 
titer of 83 units. This study concluded that age related reference values 
for ASO increase the clinical relevance of these tests.21
Fujikawa S, et al have studied the annual changes of ASO titer in 
school  children  from 1975  to  1981.  The  ULN highest  in  1975  when 
19.7% of children showed more than 500 units, the lowest in 1980 when 
20.1%  of  children  showed  more  than  80  units.  Thus  there  was  a 
significant difference in the ULN between two years; we must consider 
annual changes of ULN to make accurate diagnosis.22
Ayroub  E  M,  et  al  from  United  States  have  studied  group  A 
Streptococcal antibodies in subjects with or without rheumatic fever in 
areas  with  high  or  low  incidence  of  rheumatic  fever.  The  levels  of 
streptococcal  antibody  titer  in  population  with  or  with  out  rheumatic 
fever  from area with relatively high or  low incidence rheumatic  fever 
were  compared.  This  revealed  absence  of  consistent  difference  in  the 
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GMT between rheumatic and non rheumatic fever from high prevalent 
area.  This  contrasted  with  low  prevalent  area  where  titers  were 
significantly  higher  in  rheumatic  than  non  rheumatic.  Conclusion:  the 
presence of raised ASO in such population which probably reflects a high 
back ground prevalence of streptococcal infection, should be taken into 
consideration when evaluating the role of the group A Streptococcus in 
non purulent complications of those infections.23
Gharagozloo R, et al from Tehran, Iran have done on 3129 healthy 
individuals during summer and winter period and compared the seasonal 
variation. During summer 6% showed high titer of more than 250 IU. The 
same individual  when tested  during  winter  showed  11% having more 
than 250 IU. The seasonal difference was statistically significant.24
Cengiz AT, et al from Turkey studied ASO titer on 120 normal 
persons from different age groups. The GMT was 160.37 ± 14.08 Todd 
units. Only 20% of normal persons have had a titer over 200 Todd units25.
Naicker  GW, et  al  from Auckland have  studied on 12 year  old 
school children and ASO was determined. The mean titer did not change 
over a period of 12 months in paired samples. This showed absence of 
seasonal variation 26.
Shanthi Rajkumar, et al from Chennai screened 666 school girls for 
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repeated  sore  throat,  joint  pain  and  swelling,  chest  pain,  epistaxis, 
breathlessness,  palpitation  and  abdominal  pain  etc.  out  of  666  girls 
screened  124  showed  one  of  those  above  symptoms,  and  they  were 
screened for presence of group A Streptococcus, ASO, CRP. Of these, 
89.5%  of  children  indicated  repeated  sore  throat,  but  only  4%  were 
positive for culture. ASO, CRP levels were higher in 11 to 15 years than 
in 5 to 10 years. 27
34
STUDY JUSTIFICATION
ASO  titer  level  is  dependent  on  the  age  group,  geographical 
location,  site  of  infection  and  socio  economic  class.  Different  studies 
from different  areas  showing  different  ULN of  ASO in  different  age 
groups. 
MG Karmarkar et al  16  concluded that we have to constantly and 
periodically recheck on those very same values. Such checks may yield 
us results, which may serve as a foundation stone for further research on 
changing antigenic stimuli. They also noticed that the ULN of ASO was 
increased from 244 IU in 1991-92 to 305 in 2001-02.
Berroix X, et al  20 concluded that no significant differences were 
detected between the results in 1986-89 and those from 1978-81. Also 
Fujikawa  22  noticed  to  have  significant  difference  of  ULN  of  ASO 
between 1975 and 1980.
Sunil sethi, et al (15) also said that ULN and GMT might vary for 
children living in other regions; establishment of values in other areas 
will require additional studies. They also noticed 11 to 15 years of age 
having higher ULN than 5 to 10 years, although the difference was not 
statistically significant.
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 Renneberg,  et  al  21  also  noticed  ASO  in  sera  from  children 
increased abruptly with increasing age. 
 Study from Australia by Dandin MH, et al 27 found that age group 
6 to 9 years having higher ULN than 10 to 14 years.
 Ghargozloo R, et al  24 showed there was a seasonal difference in 
ULN of ASO, while MG Karmarkar et  al  16   and Naicker GW et al  26 
observed no seasonal variation.
No study yet done in literature comparing the socio economic variation even 
though there is a significant increase in incidence of rheumatic fever in lower socio 
economic group.
So keeping all these variations from various studies in mind, and 
no studies yet done in Chennai to find the ULN of ASO in normal healthy 
children of 5 to 15 years, this study was chosen.
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AIM OF THE STUDY 
1. To  estimate  the  upper  limit  of  normal  value  (ULN)  of 
antistreptolysin  O  in  healthy  children  of  5  to  15  years  in 
Chennai city.
2. To  compare  the  variation  in  titer  with  reference  to  age  and 
socioeconomic status.
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SUBJECTS AND METHODS
METHODOLOGY:
1) STUDY DESIGN : Descriptive study
2) STUDY PERIOD        : March 05 to September 06
3) STUDY PLACE : Corporation and Matriculation 
schools in Chennai City.
4) STUDY POPULATION : School children
    Inclusion criteria : children of 5 to 15 years
Male/ female 
   Exclusion criteria : H/o sore throat
H/o fever 
H/o arthritis
H/o antibiotic intake 
in the past three months.
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5) SAMPLE SIZE : 200 children
The GMT in 5-10 years age group is 113.7 and that in 11- 15 years 
age  group is  110.3.   With alpha error  of  5% and power  of  80%,  the 
required sample size is 100 in each group.
6) SAMPLING TECHNIQUE: Stratified random sampling 
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MANEUVER:
Two  Corporation  schools  and  two  Matriculation  schools  were 
selected  after  getting  permission  from head  of  the  institutions.  Using 
stratified random sampling technique 50 children from each school were 
included in the study. For each age group 100 children were selected and 
for  each  socio  economic  group  100  children  were  selected.  Written 
consent from each child’s parents after explaining about the procedure 
and consequences obtained.
Because there was a difficulty in extracting monthly income from 
children and parents, the Corporation school children were taken as lower 
socio  economic  group  and  children  from  Matriculation  schools  were 
taken as higher socio economic group. The samples were collected from 
July 05 to June 06 to cover seasonal variation. 
The  children  were  selected  using  above  said  inclusion  and 
exclusion criteria.  There is  no need for  fasting before sampling.  After 
cleaning the local area thoroughly with spirit and about 2 ml of blood was 
drawn  using  sterile  syringes  and  needles.  The  blood  samples  were 
transported to microbiology laboratory at Institute of Child Health and 
Hospital for Children immediately. There they were centrifuged and sera 
were separated. These separated sera were kept under -20° C still further 
use.
40
The ASO titer was estimated from those stored sera by using new 
method  called  turbidimetric  immuno  assay.  This  is  an  internationally 
accepted  method  to  determine  ASO  in  human  serum.  This  is  an 
quantitative method to estimate ASO like nephelometric method. As we 
need to have an exact value of ASO in serum, we cannot use qualitative 
methods  like  latex  agglutination,  and  the  older  methods  like  tube 
agglutination  are  very  tedious  and  cumbersome,  we  have  chosen  this 
method to know what is the exact level of ASO in the serum. Figure (1) 
shows the  ASO kit  by  which  the  determination  was  done.  Figure  (2) 
shows the semi auto analyzer, used for analysis.
Principle: 
The  turbidimetric  immuno  assay  is  based  on  the  principle  of 
agglutination.  The  test  specimen  is  mixed  with  latex  reagent  and 
activation buffer, and allowed to react.  Presence of antibody in the test 
specimen results  in formation of  an insoluble  complex resulting in an 
increase in turbidity, which is measured at 505- 578 nm wavelength. The 
increase  in  turbidity  corresponds  to  the  concentration  of  ASO  in  the 
serum.
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Figure 1 showing ASO Kit 
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Figure 2 showing Semi Auto Analyzer
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Test procedure:
 The  stored  sera  were  brought  to  room  temperature  before 
estimation. Sera were made sure that they are not hemolysed or lipemic to 
avoid false high values. The reagents also brought to room temperature 
before use.
The reagents are 
Activation buffer (R1) - ready to use buffer.
Latex  reagent  (R2)  -  ready  to  use  uniform  suspension  of 
polystyrene latex particles coated with stabilized streptolysin O.
Calibrator  –  a  lyophilized  preparation  of  ASO  positive  serum, 
which  is  equivalent  to  stated  amount  of  ASO  on  IU/ml  basis,  when 
hydrated appropriately. The strength of calibrator after reconstitution will 
be mentioned in the packet.
Calibration curve: 
The calibrator was reconstituted with 1 ml of distilled water and 
swirled to make solution homogenous after 10 minutes. Then the ASO 
calibration  curve  was  prepared  by  diluting  the  calibrator  serially  as 
mentioned below. 
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Test tube no 1 2 3 4 5
Calib.dilut. no D1 D2 D3 D4 D5
Normal saline - 100µl 100µl 100µl 100µl
Calibrator 100µl 100µl 100µl 100µl 100µl
 ASO IU/ml 800 400 200 100 50
Preparation of calibration curve was done by,  mixing 500 µl  of 
activation buffer (R1) and 50 µl of latex reagent (R2) in the measuring 
cuvette, and keeping for 5 minutes at 37ºC. Then 100 µl of calibrator D1 
was added and mixed well. The absorbance (A1) was read exactly at ten 
seconds, and also at the end of four minutes (A2). The same steps were 
repeated for each diluted calibrator D2 to D5.    ∆A (A2- A1) calculated 
for each calibrator (D1 to D5). Then a graph was plotted with ∆A versus 
concentration of ASO. 
The procedure was done with specimen in the place of calibrator, 
∆A was calculated for test specimen.  ∆A of specimen was interpolated 
on the calibration curve, and the concentration of ASO of the specimen 
was obtained. ASO titer for each samples were calculated by the same 
method as described above. 
45
STATISTICAL ANALYSIS: 
The  Geometric  Mean  Titer  (GMT)  was  obtained  for  the  titer 
values.  80th percentile  was  taken  as  the  upper  limit  (ULN)  13.  The 
significance  between  the  groups  was  determined  using  the  Mann  – 
Whitney U test. The significance was determined at 5%. 
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OBSERVATION
The upper limit  of  normal  for  whole sample is  227 IU/ml.  The 
frequency distribution of ASO titer of these 200 children is given below 
in table (1). Of these, maximum number of children are between 101 to 
150 IU/ml (26%). There are also 23.5% of children who had titer between 
50 to 100 IU/ml. Only 4.5% children are between 251 to 300 IU/ml. But 
there are about 9.5% of children who had above 300 IU/ml.
Table (1)
Distribution ranges of ASO titer:
Titer No of children Percentage
50-100 47 23.5
101-150 52 26
151-200 48 24
201-250 25 12.5
251-300 9 4.5
› 300 19 9.5
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Distribution ranges of ASO titer
50 - 100 101 - 150 151 - 200 201 - 250 251 - 300 >300
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The upper limit of normal titer for children of age group of 5 to 15 
years  including  both  lower  and  upper  socio  economic  classes  is  227 
IU/ml. The GMT for all children in study group is 147 IU/ml.
Table (2) 
GMT and ULN of children 5- 15 years in both socio economic classes:
Group GMT ULN
Over all 147 227
  
  The ULN for age group of 5 to 10 years is 233 IU/ml and for 11 to 
15 years is 216 IU/ml. Though there is a difference between these groups, 
it is not statistically significant (p=0.67). The GMT for both groups is 149 
IU/ml and 144 IU/ml respectively.
Table (3)
The comparison GMT and ULN among the age groups:    
   Age  group     GMT     ULN    p-value
   5- 10 years      149     233     0.67
   11-15 years      144     216
The ULN for  lower  socioeconomic  status  is  270 IU/ml  and for 
higher socio economic status it is 201 IU/ml. Even though there seems to 
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be a difference between these groups, it is not statistically significant. The 
GMT is 153 IU/ml and 141 IU/ml respectively.
Table(4):
The comparison of GMT and ULN among socio-economic groups:
Socioeconomic 
status
GMT ULN p-value
Low 153 270 0.56
High 141 201
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Table  (5)  shows  the  comparison  between  the  lower  and  higher 
socioeconomic classes with in the age group of 5 to 10 years. The GMT 
is  157 IU/ml among low socioeconomic group and 142 IU/ml among 
high socioeconomic group. The ULN is found to be 290 IU/ml among 
low socioeconomic group and it is 201 IU/ml among high socioeconomic 
group. The difference observed is not statistically significant (p=0.67).    
Table (5):
GMT and ULN for  the  age  group of  5-10 years  among different  socio-economic 
groups:
Socioeconomic 
class
GMT ULN p-value
Low 157 290 0.67
High 142 201
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Table  (6)  shows  difference  between  lower  and  higher 
socioeconomic class in age group of 11 to 15 years. The GMT is 149 IU/
ml  among  low  socio  economic  group  and  140  IU/ml  among  high 
socioeconomic group. The ULN is found to be 256 IU/ml among low 
socio economic group and it  is  204 IU/ml among high socioeconomic 
group.  Though  there  is  a  difference  between  two  groups,  it  is  not 
statistically significant (p=0.75).
Table (6) 
 For the age group of 11-15 years the socio-economic difference:
Socioeconomic class GMT ULN p-value
Low 149 256 0.75
High 140 204
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Comparing the titer values among age groups studied with in the 
lower socio economic class shows age 5 to 10 years having higher values 
than 11 to 15 years, is also not significant.[ Table (7); p=0.7]  
Table (7)
GMT  and  ULN  for  lower  socio-economic  class  among  different  age 
groups:
     Age group     GMT      ULN p-value
    5-10 years       157       290     0.7
    11-15 years       149        256
But among higher socioeconomic class shows that age group 11 to 
15 years have little higher value compared 5 to 10 years group, which is 
also not statistically significant. [Table (8) p=0.82]
Table (8)
GMT and ULN for higher socio-economic class among different 
age groups:
Age group GMT ULN p-value
5-10 years 142 201 0.82
11-15 years 140 204
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DISCUSSION 
One  of  the  most  important  parameter  to  identify  the  recent 
streptococcal  infection  in  a  child  who is  suspected  to  have  rheumatic 
fever is ASO titer. The evidence of recent streptococcal infection should 
be there to diagnose rheumatic fever which forms a part of Jones Criteria 
(1992)10  .The ASO titer seems to be influenced by various demographic 
factors like age, environmental factors, etc leading on to wide range of 
titer  values,  observed from different  studies  globally.  It  has also  been 
reported that the upper limit of normal titer varies over a period, even 
within the same geographical area. All these facts necessitate to define 
the  upper  limit  of  normal  for  individual  population,  as  well  as  to  be 
confirmed periodically to observe any change in the value to higher or 
lower side.
This goes without saying that the ULN of ASO titer to be redefined accordingly 
and made use for the diagnosis of acute rheumatic fever, otherwise leading to over 
or under diagnosis of acute rheumatic fever.
As  we  have  scarce  literature  on  this  subject  in  Indian  Sub 
Continent,  that  too  from  South  India  this  study  was  done  with  the 
objective of finding out GMT and ULN of ASO titer for the 5-15 Years 
age group from the Urban Population of Chennai City.
The upper  limit  of  normal  of  ASO in  the  present  study is  227 IU/ml  and the 
Geometric Mean titer is 147 IU/ml.  The table shows the comparison among the 
present study and various other studies from literature.
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Table (9): 
 Comparison of GMT and ULN of ASO titer by various studies:  
S.No Study Sample size GMT ULN
1 Present 200 147 227
2 Sunil Sethi et al 15 200 111.63 238.59
3 Karmarkar et al 16 40 --- 244, 305
4 Kaplan E L et al 18 1131 89 240
5 Zaman M M et al 19 361 241 390
6 Berriox  et al 20 135 110 ---
 
The  present  study  correlates  well  with  most  of  the  above  said 
studies. But the studies by Zaman M Met al and Karmarkar et al showed 
a higher ULN than the present study. This may be due to seasonal or 
geographic  variations.  The  socio  economic  variation  was  also  not 
mentioned in their studies. 
The ULN in 5 to 10 years is 233 IU/ml and in 11 to 15 years it is 
216 IU/ml. Though there is a difference it is not statistically significant. 
The study from Australia by Dandin, et al also observed that 6 to 9 years 
having more titer than 10 to 14 years 17. Renneberg 21 et al also observed 
age group of 9 to 12 years having high values than other age groups.
 But study by Sunil Sethi, et al 15 showed higher ULN in 11 to 15 years than 5 
to  10 years.  But this  difference was not  statistically significant.  Another  study by 
Berriox et al,  20 also showed 10 to 14 years having more GMT compared to 5 to 9 
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years. 
Children  of  5  to  10  years  are  having  more  chance  of  getting 
recurrent streptococcal infection than 10 to 15 years, which may due to 
poor hygiene, vulnerability and over crowded classrooms in 5 to 10 years. 
But the exact cause is not known. 
The children from Corporation schools  that  is  from lower socio 
economic  class  children  show  a  higher  ULN  than  for  children  from 
higher socio economic class. Though the difference observed in our study 
is not  statistically significant,  there is  well  known correlation between 
overcrowding, lower standards of living and acute rheumatic fever.  The 
children from Corporation schools are mostly from lower socioeconomic 
class  and  their  standard  of  living  also  low.  They  are  over  crowed  in 
schools as well as in houses. These may be the cause for the higher value 
among lower socio economic group. There is no study on socio economic 
variation in literature.
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SUMMARY 
• The upper limit of normal value of antistreptolysin O in the 
age group of 5 to 15 years is 227 IU/ml with in the urban 
limit of Chennai City during the period from July 2005 to 
June 2006. The geometric mean titer is 147 IU/ml. 
• The ULN of ASO in 5 to 10 years is 233 IU/ml and in 11 to 
15 years it is 216 IU/ml, and the GMT is 149 IU/ml and 
144 IU/ml respectively.
• The ULN of ASO in lower socio economic group is 270 IU/
ml, and in higher socioeconomic group is 207 IU/ml, and 
the GMT is 153 IU/ml and 141 IU/ml respectively.
• Most of the children (49.5%) are having ASO titer of less 
than 150 IU/ml. Around 9.5% of children found to have titer 
above 300 IU/ml.
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CONCLUSION
The antistreptolysin O level in healthy children of age group of 5 to 15 
years in Chennai city is 227 IU/ml.
This level can be taken as upper limit of normal, while considering 
the diagnosis of post group A Streptococcal infections in our population.
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ANNEXURE 
DATA ENTRY FORM
Name: Address:
Age:
Sex: Socio economic class:
Complaints:
H/O sore throat                    : yes / no
H/O fever                             : yes / no
 H/O antibiotic intake          :  yes / no
H/O arthritis / Arthralgia     : yes / no
Examination:
General examination:
Throat:
CVS:
Titer:
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